Alzheon
Alzheon is a privately-held biopharmaceutical company with a focus on Alzheimer's disease.
The US company has a Phase III-ready program in the disease, ALZ-801, an oral small molecule inhibitor of beta amyloid misfolding and the consequent formation of small neurotoxic aggregates, or oligomers.
Alzheon also has a discovery platform of small molecules for the treatment of neurodegenerative disorders.
Latest Alzheon News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze